OSM Human

Oncostatin-M Human Recombinant
Shipped with Ice Packs
In Stock

Description

OSM exhibits dual roles in tumor biology and inflammation:

Anti-tumor Activity

  • Inhibits proliferation in melanoma (A375), breast cancer (T47D), and erythroleukemia (TF-1) cells .

  • ED₅₀ values range from 0.05–4 ng/mL in bioassays .

Pro-inflammatory and Pro-tumorigenic Roles

  • Upregulates urokinase plasminogen activator (u-PA) and VEGF in prostate cancer, promoting metastasis .

  • Induces STAT3 phosphorylation, driving epithelial-mesenchymal transition (EMT) in epithelial cells .

Regulatory Roles

  • Modulates liver regeneration, hematopoiesis, and bone remodeling .

  • Activates JAK/STAT, MAPK, and PI3K pathways via gp130-OSMRβ/LIFR complexes .

Recombinant Production and Characterization

OSM is produced recombinantly in E. coli with high purity (≥99%) and bioactivity .

ParameterDetailsSource
Expression HostE. coli (SHuffle or BL21 strains)
Yield~10 mg/L in minimal media
Molecular Weight23.8 kDa (non-glycosylated, 210 residues)
BioactivitySTAT3 phosphorylation in T47D cells; TF-1 proliferation (ED₅₀: 0.05–0.3 ng/mL)

Post-translational cleavage (pro-OSM → mature OSM) enhances potency . Isotopic labeling (15N/13C) enables NMR-based drug screening .

Therapeutic Targeting and Clinical Relevance

OSM is implicated in inflammatory diseases (rheumatoid arthritis, COVID-19) and cancer progression .

Inhibitor Development

  • OSM-SMI-10B: Binds Site III (KD = 10–12 μM) and blocks OSMRβ interaction .

  • Monoclonal antibodies: Target OSM or OSMRβ in clinical trials for inflammatory bowel disease .

Inhibitor TypeTarget SiteAffinity/IC₅₀Mechanism
Small molecule (OSM-SMI-10B)Helix D (Site III)10–12 μMCompetitive inhibition
Anti-OSM antibodiesSoluble OSM<1 nMNeutralize circulating OSM

Future Directions

  • NMR-guided drug design: Isotope-enriched OSM enables structural mapping of inhibitor interactions .

  • Disease biomarkers: Elevated serum OSM correlates with metastatic prostate cancer and severe COVID-19 .

Product Specs

Introduction
Oncostatin M, a member of the cytokine family that also includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6, is a growth regulator. This cytokine is known to inhibit the proliferation of various tumor cell lines and regulate the production of other cytokines like IL-6, G-CSF, and GM-CSF from endothelial cells.
Description
Recombinant Human Oncostatin-M, produced in E. coli, is a single, non-glycosylated polypeptide chain comprising 227 amino acids. With a molecular weight of 26kDa, it undergoes purification using proprietary chromatographic techniques.
Physical Appearance
Sterile Filtered White lyophilized powder.
Formulation
Lyophilized from a 1mg/ml solution in phosphate-buffered saline (PBS) at pH 7.4.
Solubility
To reconstitute the lyophilized Oncostatin M, it is recommended to dissolve it in sterile 18MΩ-cm H2O to a concentration of at least 100µg/ml. This solution can then be further diluted into other aqueous solutions as needed.
Stability
Lyophilized Oncostatin M remains stable at room temperature for up to 3 weeks; however, for long-term storage, it is recommended to store it desiccated below -18°C. Upon reconstitution, Oncostatin should be stored at 4°C for 2-7 days. For extended storage, freezing below -18°C is recommended, preferably with the addition of a carrier protein like 0.1% HSA or BSA. Avoid repeated freeze-thaw cycles.
Purity
The purity is determined to be greater than 95.0% using the following methods: (a) Reverse-phase high-performance liquid chromatography (RP-HPLC) analysis, and (b) SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
Biological Activity
The ED50, determined by the dose-dependent stimulation of Human TF-1 cells, is less than 2 ng/ml. This corresponds to a Specific Activity of 500,000 IU/mg.
Protein Content
Protein quantification was performed using two independent methods: 1. UV spectroscopy at 280 nm, utilizing an absorbance value of 0.45 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated using the PC GENE computer analysis program for protein sequences (IntelliGenetics). 2. RP-HPLC analysis, employing a standard solution of Oncostatin as a reference.
Synonyms
OSM, MGC20461.
Source
Escherichia Coli.
Amino Acid Sequence
AAIGSCSKEY RVLLGQLQKQ TDLMQDTSRL LDPYIRIQGL DVPKLREHCR
ERPGAFPSEE TLRGLGRRGF LQTLNATLGC VLHRLADLEQ RLPKAQDLER
SGLNIEDLEK LQMARPNILG LRNNIYCMAQ LLDNSDTAEP TKAGRGASQP
PTPTPASDAF QRKLEGCRFL HGYHRFMHSV GRVFSKWGES PNRSRRHSPH
QALRKGVRRT RPSRKGKRLM TRGQLPR.

Q&A

What is Oncostatin M (OSM) and what role does it play in human biology?

Oncostatin M is a pleiotropic cytokine belonging to the interleukin-6 (IL-6) family that signals in multiple cell types, influencing diverse processes including cell differentiation, hematopoiesis, and inflammation . Initially isolated in 1986 from PMA-treated U-937 histiocytic lymphoma cells, OSM was identified by its ability to inhibit growth of melanoma cell lines and other solid tumors . The fully active human OSM consists of 196 amino acids, although a larger 227-residue pro-OSM form can be isolated from over-transfected cells with approximately ten-fold lower efficacy in growth inhibition assays despite similar binding affinity .

OSM is particularly notable for its stable biochemical properties, remaining functional between pH 2-11 and resistant to heating at 56°C for one hour . Like many cytokines, OSM is typically synthesized de novo and released through classical secretion pathways, though interestingly, it can also be released from preformed stores within polymorphonuclear leukocytes upon degranulation .

How does human OSM structurally compare to mouse OSM?

Human and mouse OSM share significant sequence homology, allowing for the generation of homology models based on the known human OSM structure (Protein Data Bank code 1EVS) . Structurally, both human and mouse OSM conform to the long chain four-helix bundle topology characteristic of the gp130 family of cytokines .

The three-dimensional structure of human OSM reveals a distinctive kink in helix A, resulting from a departure from the classical alpha-helical H-bonding pattern . This feature is shared with other LIFR-using cytokines and significantly affects the relative positioning of binding site III with sites I and II, which are critical for receptor interactions .

Despite their structural similarities, mouse and human OSM exhibit crucial differences, particularly in the AB loop region, which contains key amino acid residues that determine species-specific receptor activation patterns .

What receptor complexes does human OSM utilize for signaling?

Human OSM demonstrates unique signaling capabilities within the IL-6 family through its ability to bind with high affinity to two different receptor complexes:

  • LIFR/gp130 Complex: This shared complex is utilized by several IL-6 family cytokines.

  • OSMR/gp130 Complex: This is specific to OSM signaling .

This dual-receptor activation capacity distinguishes human OSM from many other cytokines and has been confirmed for rat OSM as well . In contrast, mouse OSM primarily signals through the OSMR/gp130 complex, with only limited activity through the murine LIFR . This differential receptor utilization contributes significantly to the species-specific activities observed with OSM.

What specific amino acids in the AB loop determine species-specific activities of OSM?

Research involving chimeric mouse-human OSM cytokines has identified specific amino acid residues within the AB loop that are critical for species-specific receptor recognition. In particular:

  • In mouse OSM, residues Asn-37, Thr-40, and Asp-42 are responsible for limited LIFR activation and the absence of human OSMR/LIFR signaling .

  • In human OSM, Lys-44 appears to be the main residue preventing mouse OSMR activation .

These findings were established through systematic replacement of regions within binding site III of murine OSM with human equivalents, demonstrating that the cytokine's AB loop is critical for receptor selection . The table below summarizes key amino acid differences in the AB loop that influence species-specific receptor activation:

OSM SourceKey ResiduesEffect on Receptor Activation
Mouse OSMAsn-37, Thr-40, Asp-42Limit mLIFR activation; prevent hOSMR/hLIFR signaling
Human OSMLys-44Prevents mOSMR activation

How can researchers design chimeric mouse-human OSM cytokines for translational research?

Designing chimeric mouse-human OSM cytokines for translational research involves strategic replacement of specific regions that determine receptor specificity. The methodology includes:

  • Identification of critical binding regions: Utilizing homology models based on known structures (such as hOSM's Protein Data Bank code 1EVS) to identify key binding site regions .

  • Sequence alignment and comparison: Aligning mouse and human OSM sequences using tools like ClustalW to compare critical regions, particularly the AB loop and helix D, which influence species-specific receptor recognition .

  • Strategic region replacement: Selecting different replacement lengths for each region to create chimeras that maintain structural integrity while altering receptor specificity .

  • Site-directed mutagenesis: After identifying broader regions influencing receptor specificity, performing targeted amino acid substitutions to pinpoint specific residues responsible for species-specific activities .

This approach has successfully generated mouse OSM variants with human OSM-like functional features, which facilitates preclinical studies in mice while preserving translational relevance to human biology .

What methodological approaches are optimal for studying OSM receptor activation patterns?

For studying OSM receptor activation patterns, researchers should consider the following methodological approaches:

  • Chimeric cytokine studies: Generate and compare chimeric mouse-human OSM variants to identify regions and specific amino acids critical for receptor selectivity .

  • STAT signaling analysis: Monitor differential activation of STAT proteins (particularly STAT1 and STAT3) as indicators of receptor activation. Mouse OSM exhibits STAT3-mediated but limited STAT1-mediated signaling through murine LIFR, providing a useful marker for receptor specificity .

  • Receptor binding assays: Employ radioligand binding assays to assess binding affinity toward different receptor complexes, distinguishing between binding capability and signaling efficacy .

  • Cross-species activity testing: Evaluate cytokine activity across species barriers to understand evolutionary specialization. Human OSM can signal through murine LIFR but not mouse OSMR, while mouse OSM cannot activate any human receptors, providing valuable insights into receptor-ligand co-evolution .

What is the significance of OSM's species-specific signaling in translational research?

The species-specific signaling properties of OSM have profound implications for translational research:

  • Limited cross-species functionality: Human OSM signals through murine LIFR but not mouse OSMR, while mouse OSM cannot activate any human receptors . This limitation creates challenges when translating findings from mouse models to human applications.

  • Evolutionary insights: The species-specific differences observed in OSM signaling provide a window into the evolutionary process of cytokine-receptor specialization. The mutations in the AB loop potentially reflect a key evolutionary step in which receptor promiscuity gave way to ligand-receptor specialization .

  • Engineered solutions: By understanding the molecular basis for species specificity, researchers can create mouse OSM variants that functionally mimic human OSM, facilitating more relevant preclinical studies in mouse models .

How can researchers overcome species barriers when using mouse models to study human OSM-related conditions?

To overcome species barriers when using mouse models to study human OSM-related conditions, researchers should consider:

What experimental design factors should be considered when studying post-translational modifications of OSM?

When studying post-translational modifications of OSM, researchers should consider:

  • Pro-OSM vs. mature OSM: The 227-residue pro-OSM demonstrates different biological activities compared to the fully processed 196-residue form, despite similar binding affinity in radioligand binding assays . Experimental designs should clearly distinguish between these forms.

  • Glycosylation analysis: Human OSM contains two potential N-glycosylation sites that are retained in the mature form, affecting its functional properties . Analytical techniques should account for glycosylation heterogeneity.

  • Source material considerations: OSM's properties may differ depending on whether it is isolated from naturally producing cells versus overexpression systems. The larger pro-OSM form is more readily isolated from overexpression systems, which may not reflect physiological conditions .

  • Storage conditions: Given OSM's stability across a wide pH range and temperature conditions, researchers should establish standardized storage protocols to ensure consistent activity in experimental settings .

How does the AB loop function as an evolutionary determinant in cytokine-receptor interactions?

The AB loop of OSM functions as a critical evolutionary determinant in cytokine-receptor interactions through several mechanisms:

  • Receptor selection module: The AB loop serves as a specialized receptor binding module that directs specific ligand-receptor interactions within the IL-6 family .

  • Evolutionary selection point: Mutations in this region appear to represent a key step in the evolutionary process of this cytokine, transitioning from receptor promiscuity toward ligand-receptor specialization .

  • Species barrier determinant: Specific amino acid differences in the AB loop create functional barriers between species, potentially reflecting adaptation to species-specific immunological needs .

  • Structural influence: The AB loop's configuration affects the spatial arrangement of binding sites, particularly the positioning of binding site III relative to sites I and II, which is critical for initiating signaling cascades .

This evolutionary specialization model was first proposed for the LIFR-binding site III of ciliary neurotrophic factor and later extended to the OSMR-binding site III of human OSM and the LIFR-binding site III of human LIF .

How does OSM in the context of Humanitarian OpenStreetMap Team (HOT) differ from biological Oncostatin M research?

While the acronym "OSM" is used in both contexts, they represent entirely different fields:

  • Biological OSM (Oncostatin M): A cytokine involved in cell signaling, inflammation, and multiple physiological processes .

  • Humanitarian OSM (OpenStreetMap): Refers to the Humanitarian OpenStreetMap Team (HOT), which applies open source and open data sharing principles to humanitarian response and economic development .

The Humanitarian OpenStreetMap Team was incorporated in August 2010 following the Haiti earthquake as a U.S. nonprofit organization, becoming a registered 501(c)3 charitable organization in 2013 . Their mission involves mobilizing contributors to map areas home to one billion people by 2026, connecting humanitarian actors with open mapping communities, providing remote data creation during crises, and developing open knowledge and tools .

Researchers working with "OSM Human" should be careful to specify which context they're referring to, as methodologies, tools, and research questions differ significantly between these fields.

Product Science Overview

Structure and Production

Human recombinant Oncostatin-M is typically produced using E. coli expression systems. The protein consists of 196 amino acids and has a molecular mass of approximately 22 kDa . The recombinant form is often purified to a high degree of purity, typically greater than 97%, and is available in both carrier-free and carrier-containing formulations .

Biological Functions

Oncostatin-M plays a crucial role in various physiological processes, including:

  • Hematopoiesis: It is an important regulator of the hematopoietic stem cell niche in the bone marrow .
  • Neurogenesis: OSM is involved in the regulation of neurogenesis, the process by which new neurons are formed in the brain .
  • Osteogenesis: It also plays a role in bone formation and remodeling .
Applications

Recombinant Oncostatin-M is widely used in research and therapeutic applications:

  • Cell Differentiation: It is used in the differentiation of human pluripotent stem cells into hepatocyte-like cells .
  • Cancer Research: Due to its growth-inhibitory effects on certain cancer cells, it is studied for potential therapeutic applications in oncology .
  • Inflammatory Diseases: OSM is also investigated for its role in inflammatory diseases and its potential as a therapeutic target .
Stability and Storage

Recombinant Oncostatin-M is typically lyophilized and can be reconstituted in sterile PBS. It is stable for up to 12 months when stored at -20 to -70°C and for up to 3 months after reconstitution under sterile conditions .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.